The Complete Guide to Bioidentical Hormone Replacement Therapy (BHRT)
Bioidentical hormone replacement therapy (BHRT) uses hormones structurally identical to those your body produces — most commonly estradiol, progesterone, and testosterone. It applies to both women navigating perimenopause and menopause and men with testosterone deficiency. A proper protocol begins with a full hormone panel and symptom review, not a product preference.
You've probably already done the research. You've read the articles, maybe had a conversation with a provider who didn't have much time, and come away with more questions than answers. Some sources treat BHRT as a solution to nearly everything. Others treat it as fringe medicine. Neither of those positions is accurate, and neither helps you make a good decision.
By the time most people start researching bioidentical hormone replacement therapy, they have already heard too many opinions and not enough clear explanation. One article says BHRT is the answer to every symptom. Another says hormone therapy should be avoided entirely. A provider may have told you your labs are "normal," even though you don't feel normal. Somewhere in the middle of all that noise is the question that actually matters: what is happening in your body, and is hormone therapy clinically appropriate for you?
This guide gives you a clear, evidence-grounded explanation of bioidentical hormone replacement therapy: what the term actually means, how it differs from conventional hormone therapy, who the evidence supports as candidates, what the benefits honestly look like, and what the risks actually show. At Body Balance Medical in Summerlin, Las Vegas, hormone optimization is led by Mia LoPreiato, NP, who is Biote-certified. BHRT applies to both women and men. Depending on the person, care may involve estrogen, progesterone, testosterone, or a combination — based on symptoms, lab work, and clinical fit.
BHRT is not something to choose from a menu. It should be evaluated, prescribed, and monitored.
What “Bioidentical” Actually Means
The Molecular Definition
The word "bioidentical" describes molecular structure, not marketing category. A bioidentical hormone is structurally identical — molecule for molecule — to the hormone your body produces on its own. It fits the same receptors and follows the same metabolic pathways as the endogenous version.
That's the complete definition. It does not mean "natural," "plant-derived," or "unregulated." Some bioidentical hormones are synthesized from plant precursors, but that's a manufacturing detail, not a clinical one.
The most common bioidentical hormones used clinically are estradiol (the primary estrogen active in the body), progesterone, and testosterone.
Where the Term Gets Complicated
Here's what most discussions miss: several FDA-approved medications already contain bioidentical hormones. Estradiol patches, gels, and sprays are bioidentical. Micronized progesterone — sold under brand names including Prometrium — is bioidentical and FDA-approved. You may already be receiving bioidentical hormones through a standard pharmacy prescription.
The distinction that actually matters is not bioidentical versus conventional. It's FDA-approved versus compounded. Compounded BHRT formulations are prepared by specialty pharmacies to create doses or delivery methods not commercially available. They're clinically appropriate in specific situations. They also operate under different regulatory oversight than FDA-approved products, which has practical implications for manufacturing consistency and quality assurance.
"Bioidentical" is not an FDA designation. It is clinical and marketing shorthand. Knowing that a hormone is bioidentical tells you something about what it is. It does not tell you whether a specific product is safe, consistently manufactured, or appropriate for you.
What “Bioidentical” Does Not Guarantee
Bioidentical structure does not automatically mean identical efficacy, safety, or regulatory oversight. The word describes what a hormone is — not whether a specific product is safe, tested, or appropriate for you. That distinction should be part of any honest conversation about bioidentical hormone replacement therapy.
How BHRT Differs From Conventional Hormone Therapy
What Conventional Hormone Therapy Has Typically Contained
Conventional hormone therapy has historically relied on conjugated equine estrogens — derived from horse urine — and synthetic progestins such as medroxyprogesterone acetate (MPA). These are not bioidentical. Their molecular structures differ from hormones produced by the human body.
This matters most when interpreting the Women's Health Initiative (WHI) study, which published findings in 2002 associating combined hormone therapy with elevated breast cancer risk and cardiovascular events. The WHI used conjugated equine estrogens combined with MPA — not the same compounds as estradiol and micronized progesterone. Those findings are routinely, and incorrectly, applied to all hormone therapies, including bioidentical formulations.
The Structural and Receptor-Level Difference
Synthetic progestins and bioidentical progesterone interact with hormone receptors differently. MPA binds to glucocorticoid and androgen receptors in addition to progesterone receptors — a pattern that bioidentical progesterone does not replicate. Those off-target interactions help explain the different side effect profiles between the two compounds.
Bioidentical progesterone also modulates GABA, the brain's primary calming neurotransmitter. This is part of why it tends to support sleep quality rather than disrupt it — a distinction many patients notice directly when switching from synthetic progestins.
Where the Evidence Is Clear and Where It Isn't
The tolerability difference between bioidentical progesterone and synthetic progestins is well-documented. Many women who experienced side effects on conventional combined hormone therapy tolerate bioidentical progesterone significantly better. What is less settled is the long-term comparative outcomes data. Head-to-head trials comparing BHRT to conventional therapy across cardiovascular and cancer endpoints are limited.
BHRT is structurally different and, in some cases, clinically different. That is not the same as uniformly better. The more accurate framing: molecular structure, route of delivery, dose, age, symptom pattern, medical history, and monitoring all affect the risk-benefit calculation.
Compounded vs. FDA-Approved Bioidentical Products
Pharmaceutical compounding allows a licensed pharmacy to prepare a medication based on a provider's prescription — allowing dosing flexibility or delivery forms not available through standard commercial products. That flexibility can matter for some patients.
Compounded formulations are not FDA-approved as finished products. They do not go through the same premarket review for safety, effectiveness, potency, purity, and manufacturing consistency. Both facts matter. At Body Balance Medical, the question is never simply "Can we prescribe this?" The better question is "Does this protocol make sense for this patient, and how will we monitor it responsibly?"
Who BHRT May Be Appropriate For
Women in Perimenopause and Menopause
Perimenopause is not simply "low hormones." It's a period of hormonal volatility — estrogen in particular can spike and crash within the same cycle. That unpredictability is part of what makes mood effects, sleep disruption, and cognitive changes so disorienting. As perimenopause progresses into menopause — defined as twelve consecutive months without a menstrual period — estradiol and progesterone decline become more sustained.
Common symptoms driving women to seek evaluation include hot flashes, night sweats, vaginal dryness, sleep disruption, mood instability, cognitive fog, changes in body composition, and weight that feels harder to manage. Testosterone decline is also relevant in this population, contributing to reduced libido, fatigue, and in some cases cognitive clarity.
For a deeper women's-specific overview, see the companion guide to hormone therapy for women.
Men With Testosterone Deficiency
Male testosterone levels decline gradually beginning in the mid-30s to 40s. The process is slow, which is part of why it often goes unaddressed for years. Common symptoms include low energy, reduced libido, cognitive changes, increased body fat, loss of lean muscle, and mood disruption. The clinical term for confirmed low testosterone with compatible symptoms is hypogonadism.
In February 2025, the FDA removed the boxed warning language about increased cardiovascular risk from all testosterone product labels. This followed review of the TRAVERSE trial — a 5,246-person randomized controlled trial — which found testosterone-replacement therapy was noninferior to placebo for major adverse cardiovascular events in men with hypogonadism and preexisting or high cardiovascular risk. Full study: Lincoff et al., NEJM, 2023.
The TRAVERSE data also showed higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group. Blood pressure increases were confirmed class-wide and are reflected in updated labeling. Appropriate monitoring is not optional — it is what makes the safety profile hold.
For the men's-specific protocol detail, see the companion guide to testosterone replacement therapy.
Who Is Not a Candidate
Some clinical situations represent contraindications to hormone therapy. These include:
- Personal history of hormone-sensitive cancers
- Unexplained vaginal bleeding
- Active or recent blood clotting disorders
- Uncontrolled cardiovascular disease or recent cardiac event
- Active liver disease
- Pregnancy
- Other complex medical histories that require individualized review
This is informational, not a self-screening tool. A provider who recommends BHRT without reviewing your complete health history is not doing the job correctly.
The Benefits the Evidence Supports
Vasomotor Symptom Relief
Hot flashes and night sweats are the most well-documented indication for hormone therapy across all formulations. The evidence is strong and consistent. For many women, BHRT provides relief that other interventions don't match. This is the clearest, most evidence-backed benefit in the clinical literature — and the most common reason women seek evaluation in the first place.
Sleep, Mood, and Cognitive Function
The relationship between hormones and brain function is real and mechanistic. Estrogen influences serotonin and dopamine signaling. Progesterone modulates GABA. When these hormones decline or fluctuate erratically, the neurological effects follow.
"I am tired, but I cannot sleep."
"I feel irritable in a way that does not feel like me."
"I walk into a room and forget why I am there."
"I can still function, but everything takes more effort."
BHRT is not a guaranteed mood or cognition treatment. Individual response varies, and timing matters. But when symptoms are hormonally driven, addressing the hormonal pattern can be a meaningful part of the plan. See the guide on how hormone therapy can improve sleep and mood for the mechanistic detail.
Bone Density and the Timing Hypothesis
Estrogen plays a direct role in maintaining bone mineral density. After menopause, accelerated bone loss is a real and underappreciated consequence of estrogen deficiency — and this benefit is frequently absent from conversations focused only on symptom management.
The "timing hypothesis," supported by a growing body of evidence, indicates that BHRT initiated within approximately ten years of menopause onset carries a more favorable risk-benefit profile than therapy initiated later. Timing is a clinically meaningful variable — one that should be part of any individual evaluation. This is not a blanket claim that BHRT is cardioprotective. It is an acknowledgment that when matters.
Sexual Health and Genitourinary Symptoms
Vaginal atrophy, dryness, painful intercourse, urinary urgency, and related symptoms are grouped under the clinical term genitourinary syndrome of menopause (GSM). These tend to worsen over time rather than resolve on their own. Low-dose vaginal estrogen — delivered locally via cream, tablet, or ring — has an excellent evidence profile for GSM and is distinct from systemic BHRT in both absorption and risk. Women who are not candidates for systemic therapy may still be appropriate candidates for local treatment.
Testosterone Benefits for Men and Women
In men, bioidentical testosterone therapy is associated with improvements in energy, libido, lean muscle mass, and mood — well-supported in clinical literature and now with an updated cardiovascular safety profile post-TRAVERSE.
In women, testosterone addresses reduced libido, fatigue, and in some cases mood and cognitive function. Testosterone use in women is currently off-label in the United States — not because the evidence is absent, but because no pharmaceutical company has pursued FDA approval for a female-specific product. Off-label does not mean experimental. It means a regulatory pathway hasn't been completed. See the companion post on testosterone for women: what the research actually shows.
Risks, Side Effects, and What the Research Actually Shows
The title of this article promises both risks and benefits. This section takes that seriously.
What the WHI Study Found — and What It Didn't
The 2002 WHI findings significantly changed prescribing patterns. The study identified elevated breast cancer risk and cardiovascular events associated with combined conjugated equine estrogens plus MPA in women who were, on average, 63 years old at initiation — many of them well past menopause onset.
Applying those findings to a 48-year-old woman starting bioidentical estradiol and progesterone is not scientifically supported. The populations, the hormones, and the timing are different. The WHI answered a specific question about specific drugs in a specific population. Ignoring the WHI is an oversimplification. Applying it universally to all BHRT is also an oversimplification. Good hormone care lives between those extremes.
Breast Cancer Risk
The relationship between hormone therapy and breast cancer is real and context-dependent. Combined estrogen-progestogen therapy is associated with a modest increase in breast cancer risk in some populations after several years of systemic use. Current evidence suggests the risk associated with bioidentical progesterone is lower than that associated with synthetic progestins — though this is not a guarantee.
The calculation depends on personal medical history, family history, baseline risk, type of hormone used, dose, route of delivery, duration, and whether therapy is systemic or local. This is not a reason to avoid the conversation. It is a reason to have the conversation properly.
Cardiovascular and Clotting Risks
Oral estrogen is associated with an increased risk of venous thromboembolism. Transdermal estrogen — absorbed through the skin rather than processed through the liver — appears to carry a significantly lower clotting risk. This is a first-pass metabolism difference: oral estrogen activates hepatic clotting factor pathways that transdermal delivery bypasses. Delivery method is not a cosmetic choice. It is a clinically relevant decision that affects individual risk.
Common Side Effects During Initiation
In the first weeks of BHRT, breast tenderness, mild bloating, spotting, or mood fluctuations are common. These are signals — they indicate the body is adjusting and that dose or delivery may need refinement. They are not verdicts on whether therapy will work. Most early side effects resolve with time or dose adjustment. A provider who interprets them as a reason to discontinue without exploring alternatives is not working through the full clinical picture.
The Risk of Unaddressed Hormonal Decline
Untreated hormonal deficiency is not a neutral state. Accelerated bone loss, worsening cardiovascular risk markers, cognitive effects, sexual symptoms, and significant reduction in quality of life are all associated with prolonged deficiency. These risks receive far less attention than the risks of treatment. An honest risk-benefit conversation includes both sides of the equation.
Forms and Delivery Methods — What They Mean Clinically
Option 1 Transdermal: Patches, Gels, and Creams
Transdermal delivery sends hormone through the skin and bypasses first-pass liver metabolism entirely. For estrogen, this matters: it may reduce clotting concerns for some patients compared to oral delivery. FDA-approved transdermal estradiol products are well-studied. Compounded topical preparations offer more dosing flexibility but lack the same manufacturing standardization. For most women, transdermal delivery is a preferred starting point given the more favorable clotting risk profile.
Option 2 Oral Formulations
Oral bioidentical progesterone (micronized progesterone) is FDA-approved and commonly prescribed. Many patients and providers favor it over synthetic progestins because of the GABA-mediated effects on sleep. Oral estrogen is less frequently the first-line choice due to the clotting risk profile from first-pass liver metabolism — though it remains appropriate in specific clinical contexts.
Featured Biote Hormone Pellets
Biote hormone pellets are small, custom-compounded cylinders implanted under the skin — typically in the hip — that release hormone continuously over three to five months. The defining clinical argument is consistency: no daily application, no peaks and troughs, no missed doses. For symptoms like mood instability, disrupted sleep, libido changes, and energy shifts, delivery pattern can be as important as dose.
Pellet dosing is set at insertion and cannot be adjusted mid-cycle. If a dose needs changing, the correction waits until the next insertion. This is a real consideration, and one your provider will discuss in advance. Pellets are not FDA-approved as finished products — a regulatory fact worth knowing, not a disqualifying verdict. Both Mia LoPreiato, NP and Teresa Hernandez, NP are Biote-certified, meaning protocols follow the training and standardization framework required for that delivery method. Learn more about Biote hormone pellet therapy in Las Vegas.
Option 4 Vaginal and Local Delivery
Low-dose vaginal estrogen — available as creams, tablets, and rings — addresses genitourinary symptoms with minimal systemic absorption. It is distinct from systemic BHRT in both mechanism and risk profile. Women who are not candidates for systemic therapy may still benefit from local delivery for GSM symptoms.
Option 5 Injectable Formulations
Injectable testosterone and estrogen are used in specific clinical contexts. The primary consideration with injectables is peaks and troughs — hormone levels rise after injection and decline before the next dose. Managing symptom consistency requires attention to dosing intervals and individual metabolism.
What to Expect: Evaluation, the First 90 Days, and Ongoing Care
Initial Evaluation and Lab Work
A thorough evaluation includes a comprehensive symptom review, a full hormone panel (including estradiol, total and free testosterone, progesterone, FSH, SHBG, thyroid, and cortisol at minimum), complete health history, and appropriate age-based screening. Lab values are the starting point — not the entire picture. A provider who treats only numbers without accounting for how you're actually functioning is missing critical information.
The First 90 Days
BHRT is not immediately corrective. The first weeks involve titration: finding the right dose and delivery method for your physiology. Most providers schedule follow-up at four to six weeks, with further adjustment as needed. Meaningful improvement typically takes six to twelve weeks to establish. Set expectations accordingly.
Ongoing Monitoring
BHRT requires ongoing management. Periodic labs, symptom check-ins, and dose reviews are standard. What gets monitored typically includes hormone levels, lipid panels, blood pressure, hematocrit (particularly with testosterone therapy), and any new or changing symptoms. This is not a prescription you fill once and revisit years later.
How Long Treatment Continues
There is no universal answer. The outdated recommendation to limit hormone therapy to five years is not supported by current evidence for most patients. Duration should reflect a periodic, honest evaluation of benefit, risk, and patient preference — not an arbitrary endpoint. The better question is not "How long does everyone stay on BHRT?" It is "Does continued therapy still make clinical sense for this person?"
Bioidentical HRT at Body Balance Medical
Body Balance Medical is a LegitScript-certified medical clinic in Summerlin, Las Vegas. Hormone care is provided in person — with named, credentialed providers and a full evaluation before any protocol is set. Not a telehealth intake form.
Mia LoPreiato, NP leads hormone optimization and longevity medicine. Teresa Hernandez, NP is also Biote-certified, bringing hormone and aesthetic care into the same clinical environment. Both providers are available for BHRT evaluations for women and men.
Many patients do not experience symptoms in neat categories. Sleep, weight, mood, libido, skin, energy, body composition, and mental clarity often overlap. A patient may not need "just hormones" or "just aesthetics" or "just weight loss" — they may need someone to connect the dots. That is what in-person, coordinated care provides.
For men combining testosterone therapy with GLP-1 weight loss, ask about the Balance Rate program — BBM's membership that coordinates both. You can explore the full hormone optimization program or meet both providers on the team page.
Frequently Asked Questions
What is bioidentical hormone replacement therapy?
Bioidentical hormone replacement therapy (BHRT) uses hormones with the same molecular structure as hormones your body produces. Common examples include estradiol, progesterone, and testosterone. The term describes molecular structure — not whether the product is compounded, FDA-approved, or appropriate for a specific patient.
Is bioidentical HRT safer than conventional hormone therapy?
Not automatically. Some patients tolerate certain bioidentical hormones differently than synthetic formulations, and route of delivery affects risk. But "bioidentical" does not guarantee safety. Risk depends on hormone type, dose, route, timing, duration, medical history, and monitoring. The more meaningful distinction is formulation-level, not the bioidentical label itself.
Is BHRT FDA-approved?
Some FDA-approved medications contain bioidentical hormones — estradiol patches and micronized progesterone are common examples. Compounded BHRT formulations are not FDA-approved as finished products, though they are prescribed by licensed clinicians and prepared by licensed pharmacies when clinically appropriate.
What hormones are used in BHRT?
The most common are estradiol, progesterone, and testosterone. The right protocol depends on symptoms, sex, age, lab work, and medical history. Some patients receive one hormone; others receive a combination. Candidacy and protocol are determined by clinical evaluation, not by preference.
Who is a candidate for BHRT?
Potential candidates include women in perimenopause or menopause with symptoms related to estrogen, progesterone, or testosterone changes, and men with confirmed testosterone deficiency and compatible symptoms. Candidacy cannot be determined by symptoms alone — it requires a clinical evaluation including a full hormone panel and health history review.
How long does it take for BHRT to work?
Response varies. Some patients notice changes within weeks, while others need more time for dosing, delivery method, and monitoring to settle. The first 90 days are typically used to assess symptom response and make appropriate adjustments. No specific outcome by a specific date can be promised.
What is the difference between BHRT and traditional hormone therapy?
BHRT uses hormones structurally identical to those your body produces. Traditional hormone therapy may use synthetic progestins or conjugated estrogens, depending on the product. The more clinically important distinction is the specific hormone, route, dose, timing, and monitoring plan — not the category label.
Can men use BHRT?
Yes. Men may be evaluated for testosterone therapy when symptoms and lab work support a diagnosis of hypogonadism. In February 2025, the FDA removed the cardiovascular black-box warning from testosterone products following the TRAVERSE trial, though appropriate assessment, dosing, and monitoring are still required. See the testosterone replacement therapy guide for the full picture.
Can women use testosterone as part of BHRT?
Some women may be evaluated for testosterone therapy. In the US, testosterone for women is off-label — not because the evidence is absent, but because no commercial product has gone through the FDA approval process for women specifically. The strongest consensus-supported indication is hypoactive sexual desire disorder in postmenopausal women after appropriate assessment. See the companion post on testosterone for women.
Is Biote hormone pellet therapy the same as BHRT?
Biote pellet therapy is one delivery method that may be used as part of a BHRT protocol. Pellets provide continuous hormone delivery over several months. Whether pellets are appropriate depends on symptoms, labs, medical history, and provider evaluation. Learn more about Biote hormone pellet therapy in Las Vegas.
Find Out If BHRT Fits Your Clinical Picture
If you feel like something has shifted and you haven't gotten a clear explanation, the next step is an evaluation — a full hormone panel and symptom review with a Biote-certified provider, in person.
Apply for Your Assessment
Disclaimer: The information in this article is for educational purposes only and is not a substitute for individual medical advice. Bioidentical hormone replacement therapy involves both FDA-approved medications and compounded formulations prescribed following individual clinical evaluation. Whether BHRT is appropriate for you, and which protocol fits your clinical picture, is a decision to make with a licensed clinician based on your complete health history, lab results, and symptoms. Individual results vary and are not guaranteed.